Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amicus Therapeutics (FOLD) FCF Margin (2016 - 2025)

Amicus Therapeutics (FOLD) has disclosed FCF Margin for 16 consecutive years, with 10.35% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, FCF Margin rose 1316.0% year-over-year to 10.35%, compared with a TTM value of 5.21% through Dec 2025, up 1230.0%, and an annual FY2025 reading of 5.21%, up 1230.0% over the prior year.
  • FCF Margin was 10.35% for Q4 2025 at Amicus Therapeutics, down from 20.87% in the prior quarter.
  • Across five years, FCF Margin topped out at 20.87% in Q3 2025 and bottomed at 110.27% in Q1 2021.
  • Average FCF Margin over 5 years is 28.42%, with a median of 20.6% recorded in 2023.
  • The sharpest move saw FCF Margin surged 8905bps in 2023, then crashed -3575bps in 2025.
  • Year by year, FCF Margin stood at 90.16% in 2021, then decreased by -2bps to 91.75% in 2022, then skyrocketed by 97bps to 2.7% in 2023, then decreased by -4bps to 2.81% in 2024, then soared by 469bps to 10.35% in 2025.
  • Business Quant data shows FCF Margin for FOLD at 10.35% in Q4 2025, 20.87% in Q3 2025, and 18.7% in Q2 2025.